Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2017, Article ID 8565802, 12 pages
https://doi.org/10.1155/2017/8565802
Research Article

Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with 64Cu Using NOTA and NODAGA

1Department of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden
2Turku PET Centre, University of Turku, P.O. Box 52, 20521 Turku, Finland
3Turku PET Centre, Åbo Akademi University, P.O. Box 52, 20521 Turku, Finland
4Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, 106 91 Stockholm, Sweden
5MediCity Research Laboratory, University of Turku, 20520 Turku, Finland
6Department of Oncology and Radiotherapy, Turku University Hospital, 20520 Turku, Finland
7Department of Chemistry, University of Turku, 20014 Turku, Finland
8Division of Molecular Imaging, Department of Medicinal Chemistry, Uppsala University, 751 05 Uppsala, Sweden

Correspondence should be addressed to Vladimir Tolmachev; es.uu.pgi@vehcamlot.rimidalv

Received 4 January 2017; Accepted 8 February 2017; Published 28 February 2017

Academic Editor: Ralf Schirrmacher

Copyright © 2017 Vladimir Tolmachev et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. L. Arteaga, M. X. Sliwkowski, C. K. Osborne, E. A. Perez, F. Puglisi, and L. Gianni, “Treatment of HER2-positive breast cancer: current status and future perspectives,” Nature Reviews Clinical Oncology, vol. 9, no. 1, pp. 16–32, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. A. C. Wolff, M. E. H. Hammond, D. G. Hicks et al., “Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update,” Archives of Pathology and Laboratory Medicine, vol. 138, no. 2, pp. 241–256, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. E. C. Dijkers, T. H. Oude Munnink, J. G. Kosterink et al., “Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer,” Clinical Pharmacology and Therapeutics, vol. 87, no. 5, pp. 586–592, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. E. Mortimer, J. R. Bading, D. M. Colcher et al., “Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using 64Cu-DOTA-trastuzumab PET,” Journal of Nuclear Medicine, vol. 55, no. 1, pp. 23–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Beylergil, P. G. Morris, P. M. Smith-Jones et al., “Pilot study of 68Ga-DOTA-F(ab′)2-trastuzumab in patients with breast cancer,” Nuclear Medicine Communications, vol. 34, no. 12, pp. 1157–1165, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Zhang, S. Bhatnagar, E. Deschenes, and G. M. Thurber, “Mechanistic and quantitative insight into cell surface targeted molecular imaging agent design,” Scientific Reports, vol. 6, Article ID 25424, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Keyaerts, C. Xavier, J. Heemskerk et al., “Phase I study of 68Ga-HER2-Nanobody for PET/CT assessment of HER2 expression in breast carcinoma,” Journal of Nuclear Medicine, vol. 57, no. 1, pp. 27–33, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Vazquez-Lombardi, T. G. Phan, C. Zimmermann, D. Lowe, L. Jermutus, and D. Christ, “Challenges and opportunities for non-antibody scaffold drugs,” Drug Discovery Today, vol. 20, no. 10, pp. 1271–1283, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Goldstein, J. Sosabowski, M. Livanos et al., “Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 42, no. 2, pp. 288–301, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. C. H. Nielsen, R. H. Kimura, N. Withofs et al., “PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide,” Cancer Research, vol. 70, no. 22, pp. 9022–9030, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Garousi, S. Lindbo, J. Nilvebrant et al., “ADAPT, a novel scaffold protein-based probe for radionuclide imaging of molecular targets that are expressed in disseminated cancers,” Cancer Research, vol. 75, no. 20, pp. 4364–4371, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. B. J. Hackel, R. H. Kimura, and S. S. Gambhir, “Use of 64Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging,” Radiology, vol. 263, no. 1, pp. 179–188, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Ahlgren, A. Orlova, H. Wållberg et al., “Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation Affibody molecule with a fundamentally reengineered scaffold,” Journal of Nuclear Medicine, vol. 51, no. 7, pp. 1131–1138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Sörensen, I. Velikyan, D. Sandberg et al., “Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET/CT,” Theranostics, vol. 6, no. 2, pp. 262–271, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Sandström, K. Lindskog, I. Velikyan et al., “Biodistribution and radiation dosimetry of the anti-HER2 Affibody molecule 68Ga-ABY-025 in breast cancer patients,” Journal of Nuclear Medicine, vol. 57, no. 6, pp. 867–871, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Tolmachev, T. A. Tran, D. Rosik, A. Sjöberg, L. Abrahmsén, and A. Orlova, “Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition,” Journal of Nuclear Medicine, vol. 53, no. 6, pp. 953–960, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Sörensen, D. Sandberg, M. Sandström et al., “First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule,” Journal of Nuclear Medicine, vol. 55, no. 5, pp. 730–735, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. D. W. McCarthy, R. E. Shefer, R. E. Klinkowstien et al., “Efficient production of high specific activity 64Cu using a biomedical cyclotron,” Nuclear Medicine and Biology, vol. 24, no. 1, pp. 35–43, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. V. Tolmachev, H. Lundqvist, and L. Einarsson, “Production of 61Cu from a natural nickel target,” Applied Radiation and Isotopes, vol. 49, no. 1-2, pp. 79–81, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. E. W. Price and C. Orvig, “Matching chelators to radiometals for radiopharmaceuticals,” Chemical Society Reviews, vol. 43, no. 1, pp. 260–290, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. T. J. Wadas, E. H. Wong, G. R. Weisman, and C. J. Anderson, “Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease,” Chemical Reviews, vol. 110, no. 5, pp. 2858–2902, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. Z. Cheng, O. P. De Jesus, D. J. Kramer et al., “64Cu-labeled affibody molecules for imaging of HER2 expressing tumors,” Molecular Imaging and Biology, vol. 12, no. 3, pp. 316–324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Ren, J. M. Webster, Z. Liu et al., “In vivo targeting of HER2-positive tumor using 2-helix affibody molecules,” Amino Acids, vol. 43, no. 1, pp. 405–413, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. F. Prasanphanich, P. K. Nanda, T. L. Rold et al., “[64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 30, pp. 12462–12467, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Gourni, R. Mansi, M. Jamous et al., “N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga-and 64Cu-labeled peptides for PET imaging,” Journal of Nuclear Medicine, vol. 55, no. 10, pp. 1719–1725, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Shi, H. Orbay, Y. Yang et al., “PET imaging of abdominal aortic aneurysm with 64Cu-labeled anti-CD105 antibody Fab fragment,” Journal of Nuclear Medicine, vol. 56, no. 6, pp. 927–932, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. L. K. van Dijk, C.-B. Yim, G. M. Franssen et al., “PET of EGFR with 64Cu-cetuximab-F(ab′)2 in mice with head and neck squamous cell carcinoma xenografts,” Contrast Media and Molecular Imaging, vol. 11, no. 1, pp. 65–70, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Malmberg, A. Perols, Z. Varasteh et al., “Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 3, pp. 481–492, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Strand, H. Honarvar, A. Perols et al., “Influence of macrocyclic chelators on the targeting properties of 68Ga-labeled synthetic affibody molecules: comparison with 111In-labeled counterparts,” PLoS ONE, vol. 8, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Strand, Z. Varasteh, O. Eriksson, L. Abrahmsen, A. Orlova, and V. Tolmachev, “Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo,” Molecular pharmaceutics, vol. 11, no. 11, pp. 3957–3964, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Altai, J. Strand, D. Rosik et al., “Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with 68Ga and 111In via maleimido derivatives of DOTA and NODAGA,” Bioconjugate Chemistry, vol. 24, no. 6, pp. 1102–1109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. V.-V. Elomaa, J. Jurttila, J. Rajander, and O. Solin, “Automation of 64Cu production at Turku PET Centre,” Applied Radiation and Isotopes, vol. 89, pp. 74–78, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Rajander, J. Schlesinger, M. A. Avila-Rodriguez, and O. Solin, “Increasing specific activity in Cu-64 production by reprocessing the Ni-64 target material,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 52, p. S234, 2009. View at Google Scholar
  34. M. A. Avila-Rodriguez, J. A. Nye, and R. J. Nickles, “Simultaneous production of high specific activity 64Cu and 61Co with 11.4 MeV protons on enriched 64Ni nuclei,” Applied Radiation and Isotopes, vol. 65, no. 10, pp. 1115–1120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Ahlgren, K. Andersson, and V. Tolmachev, “Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine,” Nuclear Medicine and Biology, vol. 37, no. 5, pp. 539–546, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Wållberg and A. Orlova, “Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers,” Cancer Biotherapy and Radiopharmaceuticals, vol. 23, no. 4, pp. 435–442, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. V. Tolmachev, H. Wållberg, M. Sandström, M. Hansson, A. Wennborg, and A. Orlova, “Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 3, pp. 531–539, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Westerlund, H. Honarvar, E. Norrström et al., “Increasing the net negative charge by replacement of DOTA chelator with DOTAGA improves the biodistribution of radiolabeled second-generation synthetic affibody molecules,” Molecular Pharmaceutics, vol. 13, no. 5, pp. 1668–1678, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Orlova, V. Tolmachev, R. Pehrson et al., “Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors,” Cancer Research, vol. 67, no. 5, pp. 2178–2186, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Ranyuk, R. Lebel, Y. Bérubé-Lauzière et al., “68Ga/DOTA- and 64Cu/NOTA-phthalocyanine conjugates as fluorescent/PET bimodal imaging probes,” Bioconjugate Chemistry, vol. 24, no. 9, pp. 1624–1633, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Feldwisch and V. Tolmachev, “Engineering of affibody molecules for therapy and diagnostics,” Methods in Molecular Biology, vol. 899, pp. 103–126, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Y. Hu, N. Bauer, L. M. Knight et al., “Characterization and evaluation of 64Cu-labeled A20FMDV2 conjugates for imaging the integrin αvβ6,” Molecular Imaging and Biology, vol. 16, no. 4, pp. 567–577, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Garousi, K. G. Andersson, B. Mitran et al., “PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules,” International Journal of Oncology, vol. 48, no. 4, pp. 1325–1332, 2016. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Rosestedt, K. G. Andersson, B. Mitran et al., “Affibody-mediated PET imaging of HER3 expression in malignant tumours,” Scientific Reports, vol. 5, Article ID 15226, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Tolmachev, J. Malmberg, C. Hofström et al., “Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551,” Journal of Nuclear Medicine, vol. 53, no. 1, pp. 90–97, 2012. View at Publisher · View at Google Scholar
  46. E. Vegt, M. D. Jong, J. F. M. Wetzels et al., “Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention,” Journal of Nuclear Medicine, vol. 51, no. 7, pp. 1049–1058, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. J. E. Sprague, Y. Peng, A. L. Fiamengo et al., “Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycle-amide complexes as models of peptide conjugate imaging agents,” Journal of Medicinal Chemistry, vol. 50, no. 10, pp. 2527–2535, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. T. J. Wadas and C. J. Anderson, “Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64,” Nature Protocols, vol. 1, no. 6, pp. 3062–3068, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Di Bartolo, A. M. Sargeson, and S. V. Smith, “New 64Cu PET imaging agents for personalised medicine and drug development using the hexa-aza cage, SarAr,” Organic and Biomolecular Chemistry, vol. 4, no. 17, pp. 3350–3357, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Cai, Z. Li, C.-W. Huang, R. Park, A. H. Shahinian, and P. S. Conti, “An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl)benzoic acid, for 64Cu radiopharmaceuticals,” Nuclear Medicine and Biology, vol. 37, no. 1, pp. 57–65, 2010. View at Publisher · View at Google Scholar · View at Scopus